A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.

Inclusion Criteria:

• Patient (male or female) ≥12 years of age
• ECOG (Eastern Cooperative Oncology Group) performance status ≤1
• Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate.
• Patients must be willing and able to undergo study required biopsies.
• Presence of at least one measurable lesion according to RECIST v1.1.
• Documented MAPK pathway alteration

Exclusion Criteria:

• Prior treatment with ERK inhibitors.
• History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
• Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
• Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.
• Patients with malignant disease other than that being treated in the study.
• Clinically significant cardiac disease.

Other protocol-defined exclusion criteria may apply.